DexCom Inc. (DXCM) Reports Strong Performance While Maintaining Forward Outlook

DexCom Inc. (NASDAQ:DXCM) is one of the best medical technology stocks to invest in. On February 12, DexCom Inc. (NASDAQ:DXCM) shared its Q4 2025 earnings and reported $1.26 billion in quarterly revenue. This was well ahead of the $1.25 billion that Wall Street expected, and a 13% year over year growth. According to management, this growth was fueled by robust sales of systems like the G7 and the newly launched over-the-counter Stelo for non-insulin users.

DexCom said that EPS for the quarter came in at $0.68 on a non-GAAP basis, and surpassed expectations by $0.03. Gross margins also grew by 63.5%, up from 59.4% the prior year, due to what management described as manufacturing optimizations and lower freight costs.

For the full year 2025, revenue totaled $4.662 billion, up 16% year over year, said DexCom. This exceeded the company’s updated guidance range of $4.63-$4.65 billion, as Stelo generated $130 million in sales and helped drive category adoption, noted management.

In light of the robust performance, CEO Jake Leach noted that 2025 was another great year for the company. “We significantly expanded access to DexCom CGM and launched our DexCom G7 15 Day System,” he said, and emphasized momentum from product advancements and market expansions like coverage in Québec for type 2 adults.

Looking ahead, management reiterated 2026 revenue guidance of $5.16 billion to $5.25 billion. They cited continued category expansion, Stelo’s incremental contribution (about 1% to growth), and new features.

DexCom Inc. (NASDAQ:DXCM) designs, manufactures, and sells continuous glucose monitoring (CGM) systems for people with diabetes. Its core products include the Dexcom G6 and G7 CGM devices, which provide real-time glucose readings through wearable sensors and transmit data to smartphones or insulin delivery systems.

While we acknowledge the potential of DXCM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Foreign Stocks to Buy Right Now and 11 Best AI Penny Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.